CRISPR Therapeutics AG (NASDAQ:CRSP) Stake Raised by Avantax Advisory Services Inc.

Avantax Advisory Services Inc. boosted its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) by 55.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 10,651 shares of the company’s stock after acquiring an additional 3,815 shares during the quarter. Avantax Advisory Services Inc.’s holdings in CRISPR Therapeutics were worth $362,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of CRSP. Wood Tarver Financial Group LLC bought a new stake in CRISPR Therapeutics in the fourth quarter worth about $30,000. Ameriflex Group Inc. bought a new stake in CRISPR Therapeutics in the fourth quarter worth about $36,000. NBC Securities Inc. raised its position in CRISPR Therapeutics by 156,300.0% in the first quarter. NBC Securities Inc. now owns 1,564 shares of the company’s stock worth $53,000 after acquiring an additional 1,563 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in CRISPR Therapeutics during the 4th quarter worth about $71,000. Finally, CWM LLC lifted its stake in CRISPR Therapeutics by 1,308.5% during the first quarter. CWM LLC now owns 3,803 shares of the company’s stock valued at $129,000 after buying an additional 3,533 shares in the last quarter. 69.20% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have commented on CRSP shares. Bank of America reduced their price objective on shares of CRISPR Therapeutics from $79.00 to $78.00 and set a “buy” rating for the company in a research note on Tuesday, July 22nd. Chardan Capital reaffirmed a “buy” rating and set a $82.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday. Barclays upped their price objective on shares of CRISPR Therapeutics from $42.00 to $56.00 and gave the company an “equal weight” rating in a research note on Wednesday. Needham & Company LLC reaffirmed a “buy” rating and set a $81.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday, July 8th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $105.00 price objective on shares of CRISPR Therapeutics in a research note on Friday, June 27th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $71.60.

Insider Activity at CRISPR Therapeutics

In other news, Director Simeon George purchased 989,812 shares of the stock in a transaction that occurred on Wednesday, July 16th. The stock was acquired at an average price of $52.03 per share, with a total value of $51,499,918.36. Following the purchase, the director owned 1,730,179 shares in the company, valued at $90,021,213.37. This represents a 133.69% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Naimish Patel sold 3,932 shares of the business’s stock in a transaction that occurred on Thursday, May 29th. The shares were sold at an average price of $35.94, for a total value of $141,316.08. Following the completion of the sale, the insider directly owned 6,068 shares of the company’s stock, valued at approximately $218,083.92. The trade was a 39.32% decrease in their position. The disclosure for this sale can be found here. Insiders own 4.30% of the company’s stock.

CRISPR Therapeutics Price Performance

Shares of CRSP opened at $55.96 on Friday. The company has a market capitalization of $5.09 billion, a price-to-earnings ratio of -10.31 and a beta of 1.80. CRISPR Therapeutics AG has a fifty-two week low of $30.04 and a fifty-two week high of $71.13. The business’s 50-day moving average is $51.22 and its 200-day moving average is $43.82.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Monday, August 4th. The company reported ($1.29) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.18. The business had revenue of $0.89 million during the quarter, compared to analysts’ expectations of $6.44 million. CRISPR Therapeutics had a negative return on equity of 20.05% and a negative net margin of 1,229.43%. The firm’s quarterly revenue was up 72.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.49) EPS. Equities research analysts expect that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.